Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Lingfan Xu"'
Autor:
J. Spencer Hauck, David Moon, Xue Jiang, Mu-En Wang, Yue Zhao, Lingfan Xu, Holly Quang, William Butler, Ming Chen, Everardo Macias, Xia Gao, Yiping He, Jiaoti Huang
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-13 (2024)
Abstract There are limited therapeutic options for patients with advanced prostate cancer (PCa). We previously found that heat shock factor 1 (HSF1) expression is increased in PCa and is an actionable target. In this manuscript, we identify that HSF1
Externí odkaz:
https://doaj.org/article/bc8b5034efbb427c9897f185e49dbb48
Autor:
Huan Xu, Zhixiao Liu, Dajun Gao, Peizhang Li, Yanting Shen, Yi Sun, Lingfan Xu, Nan Song, Yue Wang, Ming Zhan, Xu Gao, Zhong Wang
Publikováno v:
Molecular Metabolism, Vol 59, Iss , Pp 101466- (2022)
Cell lineage reprogramming is the main approach for cancer cells to acquire drug resistance and escape targeted therapy. The use of potent targeted therapies in cancers has led to the development of highly aggressive carcinoma, including neuroendocri
Externí odkaz:
https://doaj.org/article/e9e963c3285b4ae8876b06792c665133
Publikováno v:
Asian Journal of Urology, Vol 6, Iss 1, Pp 91-98 (2019)
Since androgen receptor (AR) signaling is critically required for the development of prostate cancer (PCa), targeting AR axis has been the standard treatment of choice for advanced and metastatic PCa. Unfortunately, although the tumor initially respo
Externí odkaz:
https://doaj.org/article/a46bbb757c1c483ca3fe4553ad88ac8b
Autor:
Yu Yin, Lingfan Xu, Yan Chang, Tao Zeng, Xufeng Chen, Aifeng Wang, Jeff Groth, Wen-Chi Foo, Chaozhao Liang, Hailiang Hu, Jiaoti Huang
Publikováno v:
Molecular Cancer, Vol 18, Iss 1, Pp 1-13 (2019)
Abstract Background MYCN amplification or N-Myc overexpression is found in approximately 40% NEPC and up to 20% CRPC patients. N-Myc has been demonstrated to drive disease progression and hormonal therapeutic resistance of NEPC/CRPC. Here, we aim to
Externí odkaz:
https://doaj.org/article/a3d71d2da9bb4e1188a64c7c443b6d70
Autor:
Jun Jing, Yi Sun, Qiang Wei, Lu Yang, Huan Xu, Lingfan Xu, Hailiang Hu, Cai Tang, Shengzhuo Liu, Ruiqi Duan, Ju Guo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Few patients with prostate cancer benefit from current immunotherapies. Therefore, we aimed to explore new strategies to change this paradigm.Methods Human tissues, cell lines and in vivo experiments were used to determine whether and how
Externí odkaz:
https://doaj.org/article/51dcfae416dd4c9089fbc6c541a9534b
Autor:
Junyi Chen, Fubo Wang, Huan Xu, Lingfan Xu, Dong Chen, Jialiang Wang, Sihuai Huang, Yiqun Wen, Longmin Fang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
BackgroundProstate cancer (PCa) is the most common malignant cancer in western developed countries, which has seriously threatened the life style and life quality of men. Its pathogenesis and causes remain indistinct. Currently, it is found that lncR
Externí odkaz:
https://doaj.org/article/8634b7f9da094d3fa44c5a2a6ee69a7e
Autor:
Yu Yin, Lingfan Xu, Yan Chang, Tao Zeng, Xufeng Chen, Aifen Wang, Jeff Groth, Wen-Chi Foo, Chaozhao Liang, Hailiang Hu, Jiaoti Huang
Publikováno v:
Molecular Cancer, Vol 18, Iss 1, Pp 1-1 (2019)
Following publication of the original article [1], the authors reported that name that appeared in published online version is incorrect. Aifeng Wang should be Aifen Wang. Corrected name is provided in the author group section above.
Externí odkaz:
https://doaj.org/article/52db3e29f2c84c9ea52dbd3cb64e0773
Autor:
Li Zhang, Pengfei Wei, Xudong Shen, Yuanwei Zhang, Bo Xu, Jun Zhou, Song Fan, Zongyao Hao, Haoqiang Shi, Xiansheng Zhang, Rui Kong, Lingfan Xu, Jingjing Gao, Duohong Zou, Chaozhao Liang
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0131336 (2015)
Penile cancer (PeCa) is a relatively rare tumor entity but possesses higher morbidity and mortality rates especially in developing countries. To date, the concrete pathogenic signaling pathways and core machineries involved in tumorigenesis and progr
Externí odkaz:
https://doaj.org/article/e0ba8153b87e4841ac8df71b7b7a2218
Autor:
William Butler, Lingfan Xu, Yinglu Zhou, Qing Cheng, J. Spencer Hauck, Yiping He, Robert Marek, Zachary Hartman, Liang Cheng, Qing Yang, Mu‐En Wang, Ming Chen, Hong Zhang, Andrew J Armstrong, Jiaoti Huang
Publikováno v:
The Journal of Pathology. 260:43-55
Autor:
Su Deng, Choushi Wang, Yunguan Wang, Yaru Xu, Xiaoling Li, Nickolas A. Johnson, Atreyi Mukherji, U-Ging Lo, Lingfan Xu, Julisa Gonzalez, Lauren A. Metang, Jianfeng Ye, Carla Rodriguez Tirado, Kathia Rodarte, Yinglu Zhou, Zhiqun Xie, Carlos Arana, Valli Annamalai, Xihui Liu, Donald J. Vander Griend, Douglas Strand, Jer-Tsong Hsieh, Bo Li, Ganesh Raj, Tao Wang, Ping Mu
Publikováno v:
Nature Cancer. 3:1071-1087
Emerging evidence indicates that various cancers can gain resistance to targeted therapies by acquiring lineage plasticity. Although various genomic and transcriptomic aberrations correlate with lineage plasticity, the molecular mechanisms enabling t